Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
In a phase 2 trial of people with biopsy-confirmed MASH, tirzepatide treatment over 52 weeks led to resolution of MASH in 34 to 53% of participants (depending on the dose used) compared with placebo
Cardiovascular disease is the leading cause of death in people with type 2 diabetes
This modification significantly reduces IGF-1 LR3's binding affinity to IGF binding proteins, which typically regulate IGF-1's availability and activity
Kuala Lumpur, Bukit Bintang, Titiwangsa, Setiawangsa, Wangsa Maju, Kepong, Segambut, Bandar Tun Razak, Cheras, Subang Jaya, Petaling Jaya, Mont Kiara, Puchong, Bandar Sunway, TTDI, Seri Kembangan, Klang, Bukit Tinggi, Damansara, Sentul, Penang, George Town, Jelutong, Gelugor, Bayan Baru, Bandar Baru Air Itam, Sungai Ara, Bukit Mertajam, Butterworth, Perai, Johor Bahru, Skudai, Bukit Indah, Gelang Patah, Senai, Pasir Gudang, Taman Daya, Taman Molek, Taman Perling, Tebrau, Danga Bay, Larkin, Nusajaya, Pontian, Masai, Setia Tropika, Desaru, Tampoi
